Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Pancreatic Neoplasms 1Cytopenia 1

Interventions

Methotrexate 11Busulfan 11Cytarabine 10fludarabine 8Daunorubicin 8Cyclophosphamide 8fludarabine phosphate 7Whole-Body Irradiation 7Etoposide 7Tacrolimus 6Mitoxantrone 5Melphalan 5Idarubicin 5Thioguanine 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Azacitidine 4thymoglobulin 3Radiotherapy 3Filgrastim 3Early Intervention, Educational 3Decitabine 3Cyclosporine 3Asparaginase 3Antilymphocyte Serum 3merphos 2luspatercept 2decitabine and cedazuridine drug combination 2Tretinoin 2Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Myelodysplastic Syndromes × ON 01910 × Clear all
NCT01241500 2020-06-30

ONTIME

Traws Pharma, Inc.

Phase 3 Completed
299 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01928537 2020-06-30

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Traws Pharma, Inc.

Phase 3 Completed
67 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡